CION Ameerpet
Understanding Your Report · Reviewed by CION Oncologists · NABH Accredited
Uterine Cancer Types — Finding Where Yours Fits
“Uterine cancer” is not one disease. It is a group of them, sharing an organ and behaving quite differently — and a good deal of the confusion women encounter comes from reading material written about one type while having another. The great majority of uterine cancers are endometrial carcinomas, arising from the lining. A minority are sarcomas, arising from the muscle and connective tissue. And within the carcinomas there are subtypes that behave very differently from one another. This page is a map rather than a full account of each — find where your own diagnosis sits, and follow it from there.
- Most start in the lining — these are the endometrial carcinomas
- Endometrioid is the commonest — and the most favourable of them
- A minority are sarcomas — a different tissue entirely, and a different disease
- Cervical cancer is separate — same organ region, different disease and different cause
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The Map, in One Table
Find the word that appears on your pathology report. Everything else follows from it.
| If your report says | It is | Where to read more |
|---|---|---|
| Endometrioid adenocarcinoma | The commonest type. Oestrogen-driven, usually low grade, usually early stage. | Type 1 endometrial cancer · endometrioid adenocarcinoma |
| Serous carcinoma | A high-grade non-endometrioid carcinoma that spreads across peritoneal surfaces. | Uterine serous carcinoma |
| Clear cell carcinoma | An uncommon high-grade non-endometrioid carcinoma. | Uterine clear cell carcinoma |
| Carcinosarcoma or MMMT | A carcinoma with sarcoma-like components. Despite the name, treated as an aggressive carcinoma. | Uterine carcinosarcoma |
| Leiomyosarcoma | A true sarcoma, arising from the muscle of the uterine wall. A different disease. | Uterine leiomyosarcoma · uterine sarcoma |
| Endometrial stromal sarcoma | A true sarcoma from the connective tissue supporting the lining. Low-grade and high-grade forms behave very differently. | Uterine sarcoma |
| Hyperplasia, with or without atypia | Not cancer at all. A precancerous or benign overgrowth of the lining. | Endometrial hyperplasia |
| Squamous cell carcinoma of the cervix | Cervical cancer — a separate disease with a different cause and different treatment. | Endometrial versus cervical cancer · cervical cancer |
On terminology: “uterine cancer”, “womb cancer” and “endometrial cancer” are used almost interchangeably in everyday speech, and for most practical purposes that is harmless — because most uterine cancer is endometrial cancer. It matters when it obscures a sarcoma, which is a genuinely different disease. The precise term is the one on your pathology report.
Did You Know? The classification that has done most to change treatment in this disease is not visible under a microscope at all. Endometrial carcinomas are now sorted into four molecular groups — POLE-mutated, mismatch repair deficient, p53-abnormal, and no specific molecular profile — and these predict behaviour better than histological appearance does. It has genuinely changed decisions: a POLE-mutated tumour behaves very favourably even when it looks aggressive down the microscope, and may warrant less treatment; a p53-abnormal tumour is managed as high risk even when its appearance is modest. This classification is built into the 2023 FIGO staging system, which is why a modern report reads differently from an older one. Sources: World Health Organization classification of tumours of female reproductive organs; The Cancer Genome Atlas integrated genomic characterisation of endometrial carcinoma; FIGO staging system for cancer of the endometrium, 2023 revision; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Three Things Your Report Says, Not One
Women often ask “what type do I have?” as though it were a single answer. In practice a pathology report gives three separate pieces of information, and they are read together.
- The histological type. What the tumour is — endometrioid, serous, clear cell, carcinosarcoma, or a sarcoma. This is what the table above is about, and it is the first thing to establish.
- The grade. How abnormal the cells look, from 1 to 3, applied only to endometrioid tumours. The non-endometrioid carcinomas are high grade by definition and are not graded. See endometrial cancer grades.
- The molecular group. POLE-mutated, mismatch repair deficient, p53-abnormal, or no specific molecular profile. Increasingly the most decisive of the three, and now part of the staging system. See MMR and MSI testing.
And then, separately from all of these, the stage — how far it has travelled — which comes from the surgery rather than from the biopsy. See FIGO staging explained. Type, grade, molecular group and stage together are what the tumour board actually discusses.
Report Full of Words You Cannot Place?
Bring it in. Forty-five minutes is enough to say exactly what it describes and what follows from it.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Find the Right Type Before You Read Anything Else
Most of the confusion in this diagnosis comes from reading about one disease while having another.
Why the Type Changes So Much
It is not merely a label. The type determines what happens at almost every stage of care.
- How thoroughly you are staged. Serous carcinoma warrants assessment of the omentum and peritoneal surfaces; a low-grade endometrioid tumour does not. Imaging is often extended beyond the pelvis for the aggressive types.
- Whether anything follows surgery. A large group with low-grade endometrioid disease need nothing at all. For serous, clear cell and carcinosarcoma, chemotherapy is considered even when the tumour appears confined to the uterus. See the adjuvant decision.
- Whether hormone treatment is an option. Endometrioid tumours frequently retain hormone receptors, which opens fertility-sparing treatment and hormonal control of advanced disease. The non-endometrioid types generally do not.
- Which additional tests are done. HER2 testing is recommended in serous carcinoma and not in endometrioid tumours. Mismatch repair testing is done on all of them.
- What follow-up watches for. Endometrioid disease recurs most often at the vaginal vault; the aggressive types are more prone to abdominal and distant recurrence, so follow-up attends to different things. See follow-up schedule.
Want Your Report Translated?
Type, grade, molecular group and stage — what each one says and what the combination means. The opinion is free.
Things That Are Not Uterine Cancer
Several common findings get confused with a cancer diagnosis. All of these are separate.
Benign
Fibroids
Benign muscular growths in the uterine wall, extremely common, and a leading cause of heavy bleeding. They do not turn into sarcomas, though a sarcoma can be mistaken for one. See heavy periods.
Benign
Adenomyosis
Lining tissue growing into the muscle wall, causing heavy painful periods and a bulky tender uterus. Benign, frequently missed for years, and not a cancer risk in itself.
Usually benign
Endometrial Polyps
Localised overgrowths of the lining. The great majority are benign, and a small minority contain hyperplasia or cancer, which is why they are removed and examined. See polyp versus cancer.
Precancer
Endometrial Hyperplasia
An overgrown lining, not a cancer. Without atypia it rarely progresses; with atypia it is a recognised precancer. See endometrial hyperplasia.
Different organ
Cervical Cancer
Arises from the cervix, is caused by persistent HPV infection, and is detected by screening. A different disease. See endometrial versus cervical.
Different organ
Ovarian Cancer
Arises from the ovaries or fallopian tubes, presents with bloating and abdominal symptoms rather than bleeding. See endometrial versus ovarian.
Why Getting the Type Right Matters First
Every subsequent decision — staging, surgery, what follows it — depends on which disease this actually is.
Slides reviewed, not just the summary line
Tumour board for every diagnosis
MMR / MSI testing as standard
45-minute consultations
Second opinions welcomed, not resented
Decisions for healing, not billing
Take The Next Step
Start With the Word on Your Own Report
Not with the search results. One appointment is usually enough to place it exactly.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Uterine Cancer Types — Frequently Asked Questions
Is uterine cancer the same as endometrial cancer?
Almost, and the distinction occasionally matters. "Uterine cancer" is a collective term for malignancies arising in the uterus, and the overwhelming majority of those are endometrial carcinomas — cancers of the lining. So the two terms are used interchangeably in everyday speech without much harm. Where it matters is that a small minority of uterine cancers are sarcomas, arising from the muscle of the uterine wall or the connective tissue supporting the lining. Those are genuinely different diseases with different symptoms, a different staging system and different treatment. The precise term for your own diagnosis is the one written on your pathology report.
What is the most common type of uterine cancer?
Endometrioid adenocarcinoma, by a wide margin. It arises from the lining of the uterus in response to prolonged oestrogen stimulation, is typically preceded by endometrial hyperplasia, is usually low grade, frequently retains oestrogen and progesterone receptors, and is generally confined to the uterus when diagnosed because it causes abnormal bleeding early. It also carries the most favourable outlook of the uterine cancers, and a large proportion of women with early low-grade disease are treated with surgery alone and need nothing afterwards. It is sometimes called Type 1 endometrial cancer, in contrast to the non-endometrioid Type 2 group.
What is the difference between a uterine carcinoma and a uterine sarcoma?
The tissue they arise from. Carcinomas arise from epithelial tissue — in this case the endometrium, the lining of the uterine cavity. Sarcomas arise from mesenchymal tissue: the smooth muscle of the uterine wall in the case of leiomyosarcoma, or the connective tissue supporting the lining in the case of endometrial stromal sarcoma. The practical consequences are substantial. Sarcomas often present as a rapidly enlarging uterine mass rather than with bleeding, are frequently missed by an endometrial biopsy because they are not growing in the cavity, use a separate FIGO staging system, and are treated with approaches drawn from sarcoma practice rather than from endometrial carcinoma.
Is carcinosarcoma a carcinoma or a sarcoma?
A carcinoma, despite the name, and this genuinely changes which treatment protocols apply. Carcinosarcoma contains both carcinoma and sarcoma-like components and was historically classified as a uterine sarcoma. It is now understood as a carcinoma in which some cells have taken on a sarcoma-like appearance, and it is classified, staged and treated as an aggressive endometrial carcinoma. If your report says carcinosarcoma — or MMMT, an older term for the same thing — the relevant material is about high-grade endometrial carcinoma rather than about leiomyosarcoma or endometrial stromal sarcoma. It is a common source of confusion for patients researching their diagnosis.
Why does my report mention molecular groups as well as a type?
Because molecular classification predicts tumour behaviour better than appearance under a microscope, and it now forms part of the staging system. Endometrial carcinomas are sorted into four groups: POLE-mutated, mismatch repair deficient, p53-abnormal, and no specific molecular profile. This has changed real decisions. A POLE-mutated tumour behaves very favourably even when it looks aggressive and may warrant less treatment rather than more, while a p53-abnormal tumour is managed as high risk even when the stage and grade appear modest. Mismatch repair deficiency additionally identifies women who may respond to immunotherapy and who should be offered Lynch syndrome counselling.
Medical disclaimer: This page provides an overview of the types of uterine cancer and is reviewed by a CION oncologist, following the World Health Organization classification and current NCCN and ESGO–ESTRO–ESP guidance. It is an orientation to how these diseases are classified rather than a full account of any one of them, and it is not an interpretation of your own pathology report. Treatment decisions should be made with the oncology team holding your full pathology.